Feldmann, Georg <br/><br/>
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.  [electronic resource] 

 -  Cancer biology & therapy  Oct 2011 
 - 598-609 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.4161/cbt.12.7.16475  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Bridged Bicyclo Compounds, Heterocyclic--administration & dosage<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cyclic N-Oxides<br/>Cyclin-Dependent Kinases--antagonists & inhibitors<br/>Deoxycytidine--administration & dosage<br/>Drug Resistance, Neoplasm--genetics<br/>Enzyme Inhibitors--pharmacology<br/>Humans<br/>Indolizines<br/>Male<br/>Mice<br/>Mice, Nude<br/>Pancreatic Neoplasms--drug therapy<br/>Phosphorylation--drug effects<br/>Pyridinium Compounds--administration & dosage<br/>Receptors, Notch--genetics<br/>Retinoblastoma Protein--metabolism<br/>Signal Transduction<br/>Transforming Growth Factor beta--metabolism<br/>Xenograft Model Antitumor Assays<br/>ral GTP-Binding Proteins--metabolism<br/>Gemcitabine